Olufunmilayo Olopade to Paclitaxel
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Paclitaxel.
Connection Strength
0.932
-
Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
Score: 0.414
-
Breast Cancer Risk-Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Mol Cancer Res. 2019 11; 17(11):2244-2256.
Score: 0.145
-
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019 05; 18(5):873-885.
Score: 0.140
-
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clin Breast Cancer. 2016 Jun; 16(3):e61-3.
Score: 0.114
-
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
Score: 0.039
-
HIF-2a promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res. 2018 Oct 19; 37(1):256.
Score: 0.034
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
Score: 0.029
-
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
Score: 0.016